Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03133221 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | PHASE2 | COMPLETED | 17 | — | — | Oct 23, 2017 | Sep 29, 2024 | Jun 27, 2025 | 3 | United States |
The proportion of patients who discontinued the study due to Zydelig-related adverse events.
| Arm | Type | Description |
|---|---|---|
| Oral Zydelig 150 mg BID | EXPERIMENTAL | Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity. |
| Name | Type | Description |
|---|---|---|
| Zydelig | DRUG | Zydelig given at 150mg continuously in 28-day cycles |
Inclusion Criteria: 1. Histologically documented (by HPI or pathology report) iNHL as defined by follicular lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma/Waldenstrom disease (LPL/WM) and small lymphocytic lymphoma (SLL) or tiNHL as defined by large B cell transformation of...